Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer

Eleni Andreopoulou, Darci Gaiotti, Eugene Kim, Matthew Volm, Ruth Oratz, Robin Freedberg, Andrea Downey, Charles L. Vogel, Stephen Chia, Franco Muggia

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Background: Few studies have evaluated concomitant pegylated liposomal doxorubicin (PLD) plus trastuzumab as therapy for HER2-overexpressing metastatic breast cancer (MBC). This open-label, prospective, phase II trial assessed the safety and efficacy of this regimen, with cardiac tolerance as the principal focus. Patients and Methods: Women with HER2-overexpressing recurrent MBC, baseline left ventricular ejection fractions 55%, and no history of serious cardiac illness were eligible; preexisting cardiac riskfactors, including previous anthracyclines and previous trastuzumab for MBC, were allowed. Patients received weekly trastuzumab and every-3-week PLD until progression, prohibitive toxicity, or patient refusal. Left ventricular ejection fraction was assessed during and aftertherapy. Grade 3/4 congestive heart failure (CHF) was monitored for premature closure. Results: The trial closed after 2.5 years for slow accrual. Twelve patients were enrolled: 7 had received adjuvant anthracyclines; 9 had received previous MBC treatment, of whom 7 had received trastuzumab in combination with chemotherapy. Patients received a mean of 4.8 cycles of PLD; 8 patients experienced stable disease; 4 patients experienced progression. Mean left ventricular ejection fraction levels did not change substantially: 60.4%, 57%, 60.3%, and 56.8% at baseline, after cycle 2, after cycle 4, and after completion of treatment, respectively. No patients experienced grade 4 CHF. One patient discontinued treatment after grade 3 CHF. Three patients experienced grade 2 left ventricular dysfunction, of whom 2 discontinued treatment. Cardiac function improved in all 4 patients after going off study. Other adverse events were generally mild (grade 1/2) and infrequent. Conclusion: Pegylated liposomal doxorubicin plus trastuzumab might be an option for heavily pretreated patients with recurrent HER2-overexpressing MBC.

Original languageEnglish (US)
Pages (from-to)690-696
Number of pages7
JournalClinical breast cancer
Volume7
Issue number9
DOIs
StatePublished - Aug 2007
Externally publishedYes

Keywords

  • Anthracyclines
  • Congestive heart failure
  • Left ventricular ejection fraction

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this